Variation in pre-PCR processing of FFPE samples leads to discrepancies in BRAF and EGFR mutation detection: A diagnostic RING trial

Journal of Clinical Pathology

Volumn 68, Issue 2, 2015, Pages 111-118

  Kapp, Joshua R ^a   Diss, Tim ^a   Spicer, James ^b   Gandy, Michael ^a   Schrijver, Iris ^c   Jennings, Lawrence J ^d   Li, Marilyn M ^e   Tsongalis, Gregory J ^f   De Castro, David Gonzalez ^g   Bridge, Julia A ^h   Wallace, Andrew ⁱ   Deignan, Joshua L ^j   Hing, Sandra ^k   Butler, Rachel ^l   Verghese, Eldo ^m   Latham, Gary J ⁿ   Hamoudi, Rifat A ^a  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

^b GUY'S AND ST THOMAS' NHS FOUNDATION TRUST   (United Kingdom)

^c STANFORD UNIVERSITY MEDICAL CENTER   (United States)

^d NORTHWESTERN UNIVERSITY   (United States)

^e BAYLOR COLLEGE OF MEDICINE   (United States)

^f DARTMOUTH HITCHCOCK MEDICAL CENTER   (United States)

^g INSTITUTE OF CANCER RESEARCH   (United Kingdom)

^h UNIVERSITY OF NEBRASKA MEDICAL CENTER   (United States)

ⁱ MANCHESTER UNIVERSITY NHS FOUNDATION TRUST   (United Kingdom)

^j UNIVERSITY OF CALIFORNIA   (United States)

^k GREAT ORMOND STREET HOSPITAL   (United Kingdom)

^l CARDIFF AND VALE UNIVERSITY HEALTH BOARD   (United Kingdom)

^m UNIVERSITY OF LEEDS   (United Kingdom)

ⁿ ASURAGEN INC   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

FORMALDEHYDE; PARAFFIN; B RAF KINASE; BRAF PROTEIN, HUMAN; DNA; EGFR PROTEIN, HUMAN; EPIDERMAL GROWTH FACTOR RECEPTOR; FIXATIVE;

ARTICLE; BRAF GENE; CLINICAL TRIAL (TOPIC); CONTROLLED STUDY; DNA DETERMINATION; DNA EXTRACTION; EGFR GENE; FLUOROMETRY; GENE MUTATION; HUMAN; HUMAN CELL; HUMAN TISSUE; MEASUREMENT ACCURACY; ONCOGENE; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; SPECTROPHOTOMETRY; CLINICAL TRIAL; COMPARATIVE STUDY; DIAGNOSTIC ERROR; DNA MUTATIONAL ANALYSIS; GENETIC TRANSFECTION; GENETICS; GOOD LABORATORY PRACTICE; GREAT BRITAIN; ISOLATION AND PURIFICATION; MULTICENTER STUDY; MUTATION; OBSERVER VARIATION; PREDICTIVE VALUE; PREVENTION AND CONTROL; PROCEDURES; REPRODUCIBILITY; STANDARDS; TISSUE FIXATION; TUMOR CELL LINE; UNITED STATES; WORKFLOW;

CELL LINE, TUMOR; DIAGNOSTIC ERRORS; DNA MUTATIONAL ANALYSIS; DNA, NEOPLASM; FIXATIVES; FLUOROMETRY; FORMALDEHYDE; GREAT BRITAIN; HUMANS; LABORATORY PROFICIENCY TESTING; MUTATION; OBSERVER VARIATION; PARAFFIN EMBEDDING; POLYMERASE CHAIN REACTION; PREDICTIVE VALUE OF TESTS; PROTO-ONCOGENE PROTEINS B-RAF; RECEPTOR, EPIDERMAL GROWTH FACTOR; REPRODUCIBILITY OF RESULTS; SPECTROPHOTOMETRY; TISSUE FIXATION; TRANSFECTION; UNITED STATES; WORKFLOW;

EID: 84961291408     PISSN: 00219746     EISSN: 14724146     Source Type: Journal    
DOI: 10.1136/jclinpath-2014-202644     Document Type: Article

References (30)

1. Fukuoka M, Wu YL, Thongprasert S, et al. Biomarker analyses and final overall survival results from a phase III, randomized, open-label, first-line study of gefitinib versus carboplatin/paclitaxel in clinically selected patients with advanced non-small-cell lung cancer in Asia (IPASS). J Clin Oncol 2011;29:2866-74.
2. Lynch TJ, Bell DW, Sordella R, et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med 2004;350:2129-39.
3. Maemondo M, Inoue A, Kobayashi K, et al. Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR. N Engl J Med 2010;362:2380-8.
4. Mitsudomi T, Morita S, Yatabe Y, et al. Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial. Lancet Oncol 2010;11:121-8.
5. Mok TS, Wu YL, Thongprasert S, et al. Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N Engl J Med 2009;361:947-57.
6. Han SW, Hwang PG, Chung DH, et al. Epidermal growth factor receptor (EGFR) downstream molecules as response predictive markers for gefitinib (Iressa, ZD1839) in chemotherapy-resistant non-small cell lung cancer. Int J Cancer 2005;113:109-15.
7. De Roock W, Claes B, Bernasconi D, et al. Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis. Lancet Oncol 2010;11:753-62.
8. Esfahani K, Agulnik JS, Cohen V. A systemic review of resistance mechanisms and ongoing clinical trials in ALK-rearranged non-small cell lung cancer. Front Oncol 2014;4:174.
9. Poulikakos PI, Persaud Y, Janakiraman M, et al. RAF inhibitor resistance is mediated by dimerization of aberrantly spliced BRAF(V600E). Nature 2011;480:387-90.
10. Tsiatis AC, Norris-Kirby A, Rich RG, et al. Comparison of Sanger sequencing, pyrosequencing, and melting curve analysis for the detection of KRAS mutations: diagnostic and clinical implications. J Mol Diagn 2010;12:425-32.
11. Kalman LV, Lubin IM, Barker S, et al. Current landscape and new paradigms of proficiency testing and external quality assessment for molecular genetics. Arch Pathol Lab Med 2013;137:983-8.
12. Blum F. Der Formaldehyde als Hartungsmittel. Z wiss Mikr 1893;10:314-5.
13. Rait VK, Zhang Q, Fabris D, et al. Conversions of formaldehyde-modified 2′-deoxyadenosine 5′-monophosphate in conditions modeling formalin-fixed tissue dehydration. J Histochem Cytochem 2006;54:301-10.
14. Dhaliwal A. DNA Extraction and Purification. Labome 2014;3:191. http://dx.doi.org/10.13070/mm.en.3.191
15. Sedlackova T, Repiska G, Celec P, et al. Fragmentation of DNA affects the accuracy of the DNA quantitation by the commonly used methods. Biol Proced Online 2013;15:5-15.
16. Glasel JA. Validity of nucleic acid purities monitored by 260 nm/280 nm absorbance ratios. Biotechniques 1995;18:62-3.
17. Simbolo M, Gottardi M, Corbo V, et al. DNA qualification workflow for next generation sequencing of histopathological samples. PLoS ONE 2013;8:e62692.
18. van Dongen JJ, Langerak AW, Bruggemann M, et al. Design and standardization of PCR primers and protocols for detection of clonal immunoglobulin and T-cell receptor gene recombinations in suspect lymphoproliferations: report of the BIOMED-2 Concerted Action BMH4-CT98-3936. Leukemia 2003;17:2257-317.
19. Langerak AW, Groenen PJ, Bruggemann M, et al. EuroClonality/BIOMED-2 guidelines for interpretation and reporting of Ig/TCR clonality testing in suspected lymphoproliferations. Leukemia 2012;26:2159-71.
20. Sah S, Chen L, Houghton J, et al. Functional DNA quantification guides accurate next-generation sequencing mutation detection in formalin-fixed, paraffin-embedded tumor biopsies. Genome Med 2013;5:77.
21. Nolan T, Hands RE, Ogunkolade W, et al. SPUD: a quantitative PCR assay for the detection of inhibitors in nucleic acid preparations. Anal Biochem 2006;351:308-10.
22. Patton S, Normanno N, Blackhall F, et al. Assessing standardization of molecular testing for non-small-cell lung cancer: results of a worldwide external quality assessment (EQA) scheme for EGFR mutation testing. Br J Cancer 2014;111:413-20.
23. Foley C, O'Farrelly C, Meade KG. Technical note: Comparative analyses of the quality and yield of genomic DNA from invasive and noninvasive, automated and manual extraction methods. J Dairy Sci 2011;94:3159-65.
24. Gilbert MT, Haselkorn T, Bunce M, et al. The isolation of nucleic acids from fixed, paraffin-embedded tissues-which methods are useful when? PLoS ONE 2007;2:e537.
25. Deben C, Zwaenepoel K, Boeckx C, et al. Expression analysis on archival material revisited: isolation and quantification of RNA extracted from FFPE samples. Diagn Mol Pathol 2013;22:59-64.
26. Haque KA, Pfeiffer RM, Beerman MB, et al. Performance of high-throughput DNA quantification methods. BMC Biotechnol 2003;3:20.
27. O'Neill M, McPartlin J, Arthure K, et al. Comparison of the TLDA with the Nanodrop and the refernce Qubit System. J Phys 2011;307:1-6.
28. McPherson MJ, Hames BD, Taylor GR. PCR 2: A practical approach. Oxford University Press, 1995;7:1-12.
29. Sachse K, Frey J. PCR detection of microbial pathogens. Introduction. Methods Mol Biol 2003;216:v-vi.
30. Patton S, Thunnissen E, Blackhall F, et al. (Round 2) Pilot EQA scheme for EGFR mutation testing in non-small cell lung cancer. 2012;2.